Secondary Logo

Journal Logo

Left ventricular mass index and subendocardial myocardial function in children with chronic kidney disease, a transmural strain and three-dimensional echocardiographic study

Tantawy, Amira Esmat Ela; Fadel, Fatinab; Abdelrahman, Safaa M.b; Nabhan, Marwab; Ibrahim, Reema; Fattouh, Aya M.a; Sayed, Shaimaa Elb; ElKhashab, Khaled Mohamedc; Afdal, Peterd; AbdelMassih, Antoine Fakhrya

Cardiovascular Endocrinology & Obesity: December 2019 - Volume 8 - Issue 4 - p 115–118
doi: 10.1097/XCE.0000000000000186
Original Articles
Free

Introduction Left ventricular hypertrophy (LVH) is the commonest myocardial response to chronic kidney disease (CKD); this response has been regarded detrimental as it impairs the blood flow to the deepest layers of the myocardium causing progressive myocardial dysfunction. The aim of these series is to assess the determinants of LVH in CKD patients and its impact on subendocardial function in such patients.

Methods This study has been conducted on 40 CKD patients (Group 1) and 40 age-matched controls, both groups were assessed by transmural echocardiography to determine the subepicardial and subendocardial global longitudinal strain (GLS) as an expression of the systolic function of each of those layers. LVH was assessed by calculation of left ventricle mass index (LVMI). Both groups underwent ambulatory blood pressure monitoring. Group 1 was assessed as regards lipid profile and insulin resistance by homeostasis model assessment of insulin resistance (HOMA-IR).

Results HOMA-IR proved to be a more important determinant of LV hypertrophy than SBP and DBP with a P of 0.01. Moreover subendocardial GLS was negatively correlated with LVMI with r = 0.69 and P < 0.01 denoting the negative effect. LVH plays on subendocardial function probably by impairing myocardial perfusion.

Conclusion This study points toward the importance of insulin resistance in aggravation of myocardial remodeling in CKD patients; more studies are warranted to examine the role of insulin Sensitizers in reversing such remodeling and restoring subendocardial function in such important systemic disorder.

aPediatric Cardiology

bPediatric Nephrology

cPediatrics

dInternship Program, Faculty of Medicine, Cairo University, Cairo, Egypt

Received 3 July 2019 Accepted 30 September 2019

Correspondence to Antoine Fakhry AbdelMassih, Lecturer of Pediatrics and Pediatric Cardiology, Faculty of Medicine, Cairo University, Cairo PO Box 12411, Egypt, E-mail: antoine.abdelmassih@kasralainy.edu.eg

Back to Top | Article Outline

Introduction

Left ventricular hypertrophy (LVH) is a common and important form of cardiac remodeling in the context of chronic kidney disease (CKD) [1]. This concentric remodeling is more common than eccentric remodeling in patients with CKD. For years, it was believed that the extent of concentric remodeling in CKD is directly related with the degree of systemic hypertension [2]. This solid belief has markedly regressed over the last years. It is now increasingly evident that LVH is not a uniform process and is rather a multifactorial disease than single factor disorder. Metabolic and genetic abnormalities are thought to impact LV type and rapidity of remodeling. Buono et al. [3] demonstrated in his retrospective series in 2013 that LVH is better linked to BMI rather than systolic blood pressure. Watanabe et al. [4] demonstrated that insulin resistance which is a common metabolic abnormality encountered in CKD patients is closely linked to LVH [5]. El Saiedi et al. [6] demonstrated in recent studies that obesity operates by causing left ventricular diastolic dysfunction even in the absence of LVH. The linkage between hyperinsulinism and LVH has also been elucidated in neonates born with of congenital hyperinsulinism and infants of diabetic mothers [6]. This linkage can explain the findings of Buono et al. [3] that high BMI is associated with LVH as with higher BMI insulin resistance rises progressively and this might be the underlying etiology behind LVH in CKD patients.

It is also well recognized that subendocardial ischemia develops with progressive LVH due to the progressive decline of blood flow to the subendocardium with myocardia thickening. The subendocardium is the least vascular layer of the myocardium being supplied by the tiniest peripheral branches of the large epicardial coronary branches. The detrimental effect of LVH on myocardial perfusion and the mentioned relationship between insulin resistance and LVH are poorly examined in the context of CKD. A new technique termed transmural strain has recently been elucidated to allow discrimination if the observed myocardial dysfunction is mainly related to the subendocardial involvement or subepicardial injury [6]. The presence of such a new technique might allow the recognition of early subendocardial involvement in CKD and to study its relationship with LVH and the best determinants of both. This is the exact goal of this research. Such understanding of those pathogenetic relationships might help to initiate new therapeutic strategies such as early placement of insulin sensitizers for myocardial protection in patients with CKD

Back to Top | Article Outline

Study subjects

This case-control cross-sectional study was conducted from September 2017 to September 2018; it included two groups: Group 1: 40 patients with CKD were enrolled from Nephrology unit in Cairo University Children Hospital. Exclusion criteria included arrhythmia, congenital or acquired heart disease or diabetes mellitus as proved by oral glucose tolerance test (OGTT). Group 2: 40 healthy age and sex matched controls collected from general outpatient clinics in Cairo University Children Hospital among children coming for well child checkup and those who have upper respiratory tract infections

Written and informed consent was obtained from all the study participants legal guardians. The study was approved by the local ethics committee of Cairo University.

Back to Top | Article Outline

Study methods

For the two study groups the following was performed.

Continuous blood pressure monitoring with average daytime and night time Blood Pressure calculated.

Echocardiographic assessment: Transthoracic echocardiography was performed using General Electric (Vivid-7/9, Horten, Norway) machine with 3- and 5-MH transducers according to the age of the patient and having tissue velocity imaging capabilities [7,8].

Two-dimensional Speckle tracking myocardial layer strain discriminating echocardiography (MLSD-STE or transmural strain) of the left ventricle: (1) The endocardial border of the heart was manually traced at end systole; (2) the software automatically then detected and calculated for each of the 17 segments the longitudinal strain (shortening) of the subepicardial layer of the myocardium alternatively called ‘Epicardial Strain’ (Epi-S) and that of subendocardial layer of the myocardium alternatively known as ‘Endocardial Strain’ (Endo-S) and the average of both known as mid-myocardial strain or simply myocardial strain ; and (3) the average of the 17 segments was then calculated for each of the three longitudinal strain values to calculate the mid-myocardial strain alternatively called global longitudinal strain (GLS) and the subepicardial GLS and subendocardial GLS.

Three-dimensional echocardiography: Full-volume acquisition of the LV was obtained by harmonic imaging from the apical approach. Six ECG-gated consecutive beats were acquired during end-expiratory breath-hold to left ventricular full volume. The software automatically identified the left ventricular cavity endocardial border. The operator performed all the necessary adjustments manually in order to correctly place the endocardial border. After the adjustments software provided the left ventricular volumes, ejection fraction and left ventricular mass, left ventricular mass was subsequently indexed to body surface area to calculate LV mass index (LVMI). Three-dimensional echocardiography was relied upon for calculation of LVMI instead of motion-mode echocardiography having the narrowest reported intermethod variability (<3%) when compared to standard cardiac MRI.

For the Group 1, only additional data were performed as follows.

Biochemical assessment included serum creatinine, urea, cholesterol, triglycerides all in milligram per deciliter (mg/dl). Homeostasis model assessment of insulin resistance (HOMA-IR) will be quantified using the following equation: Fasting insulin (after 12 hours of fasting) (µU/ml) × fasting glucose (mmol/l)/22.5 calculated to determine the severity of insulin resistance in each group of patient; it has as well the advantage of being easily performed unlike OGTT which depends on serial serum glucose measurements [9].

Back to Top | Article Outline

Results

Table 1 shows the measured demographic, clinical, laboratory and echocardiographic parameters in the two study groups. It clearly shows higher BMI in CKD patients. Moreover, blood pressure was statistically higher in cases compared with controls.

Table 1

Table 1

Subendocardial systolic function as expressed by subendocardial GLS was significantly lower in CKD patients while subepicardial GLS was comparable between the two groups.

Table 2 is a multivariate analysis showing that the best predictor of LVH in CKD patients is insulin resistance compared with systemic hypertension.

Table 2

Table 2

Figure 1 is a scatter plot confirming the tight relationship between LVMI and subendocardial function with r = −0.69

Fig. 1

Fig. 1

Back to Top | Article Outline

Discussion

CKD is an important cause of myocardial dysfunction. Cardiovascular complications are considered the most important causes of death in CKD patients. Whether these complications are related to endothelial dysfunction, pericardial disease, infective endocarditis from catheter related infections and last but not least myocardial dysfunction [10,11].

One of the most important strategies followed to alleviate the risk of myocardial dysfunction in CKD was the strict control of blood pressure. This strategy was based as mentioned before on a nearly false fixed belief that myocardial remodeling occurring in CKD is induced directly and only by systemic hypertension; the latter was regarded as the only risk factor for progressive LVH seen in those cases [12].

Recently, more focus has been given to the metabolic syndrome occurring in patients with CKD, most patients with CKD develop obesity. This is due to several risk factors, some related to the state of disease they are suffering from such as stagnation, long dialysis hours while some others are related to obesity epidemic the world is facing in the previous few years; this obesity epidemic has been mainly linked to long screen times and lack of physical activities, especially among children. This prevalence of obesity has been confirmed in our series; the BMI of cases was markedly higher than the BMI of age matched controls. This state of obesity in CKD patients induces a cascade of metabolic abnormalities that might also be aggravated by the renal insufficiency in such patients. Our study subjects displayed dyslipidemia in the form of mainly high Triglycerides. This finding goes in agreement with previous analyses of lipid abnormalities in obese patients in which hypertriglyceridemia prevails over hypercholesterolemia [13–15].

Insulin resistance and subsequent hyperinsulinemia are two common sequelae of obesity. Insulin resistance has been as well linked to molecular mechanisms in skeletal muscles that are directly related to CKD state and not only to the observed obesity in such patients. Moreover, CKD reduces insulin clearance, therefore, exacerbating hyperinsulinemia. Insulin resistance has been confirmed to aggravate CKD by altering renal hemodynamics, filtration pressure and aggravating sodium retention and therefore hypertension. The role hyperinsulinemia plays in myocardial remodeling is well known in the recent literature [16,17]. Insulin causes myocardial hypertrophy, impairs diastolic function and aggravates systemic hypertension by impairing endothelia function.

In our series insulin resistance was assessed by HOMA-IR, being less invasive, inexpensive and less labor-intensive method to measure insulin resistance. However, HOMA-IR validity should be carefully considered in subjects with a lower BMI, a lower beta cell function, and high fasting glucose levels such as lean type 2 diabetes mellitus with insulin secretory defects.

In our study subjects, hyperinsulinemia reached a level far beyond the cutoff (3.5) by HOMA-IR.

Moreover, among all assessed numerical parameters, insulin resistance proved itself the best predictor of LVH as measured by LVMI. BMI did not achieve enough statistical significance in determining or predicting LVH in CKD patients. The latter finding disagrees with Buono et al. [3] series which reportedly shows a high correlation between BMI and LVH in hypertensive patients. This is not the first study to implement myocardial strain analysis in CKD patients, and Ravera et al. [18] and his team are the last to publish a series about GLS involvement in CKD. GLS has the advantage over conventional fractional shortening in taking into account the segmental myocardial involvement.

Despite the extensive studies pointing at the early reduction of GLS in CKD patients, none have used the technique implemented in this study. The relatively new echocardiographic modality termed transmural strain made it possible to understand whether LV systolic dysfunction seen in any systemic disease is mainly related to the subendocardium or subepicardium. The subepicardium is more vulnerable when it comes to deposition disorders such as iron load while the subendocardium [6] is more commonly involved when the systemic disease in question operates by ischemia. This new aspect has many advantages as it might detect myocardial dysfunction involving a certain layer earlier than GLS and it might uncover the mechanism underlying myocardial involvement. In our series, there was definite reduction of subendocardial GLS in cases compared with controls, while subepicardial strain was preserved. Nevertheless, subendocardial GLS has been negatively correlated with LVMI, as the thickness of the myocardium increases there is gradual distancing of supplying microvasculature from the relatively ischemic subendocardium leading to aggravation of its ischemic state. There is also increasing body of evidence that insulin resistance by itself operates by inducing endothelial dysfunction and this might as well cause the observed subendocardial dysfunction [18].

Back to Top | Article Outline

Conclusion

This study examines the role of insulin resistance in induction of myocardial remodeling in CKD; the findings identified in this study might represent a new hope for reverse remodeling of the myocardium in such patients. It highlights the fact that insulin resistance is by far given the factors studied is the most important triggering factor of LVH in CKD, and this impacts myocardial function, especially the subendocardium probably by impairing its perfusion. This near to be the fact need more studies to examine the role of insulin sensitizers in reversing the observed remodeling in CKD patients even in the absence of diabetes.

Back to Top | Article Outline

Acknowledgements

We want to thank our patients for being our source of knowledge but also we want to thank our students, interns and residents for being our source of passion, we wake up everyday with the negative thoughts of giving up; yet meeting these passionate young colleagues, teaching them and working hand in hand with them help to regenerate our positive vibes.

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

References

1. Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment.Cardiorenal Med. 2015; 5:254–266
2. Katholi RE, Couri DM. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications.Int J Hypertens. 2011; 2011:495349
3. Buono F, Crispo S, Pagano G, Rengo G, Petitto M, Grieco F, et al. Determinants of left ventricular hypertrophy in patients with recent diagnosis of essential hypertension.J Hypertens. 2014; 32:166–173
4. Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H. Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension.Journal Of Hypertension. 1999; 17:1153–1160
5. Nyström N, Sundström J, Zethelius B, Lind L, Lithell HO, Hales CN, Andrén B. Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men.Circulation. 2012; 101:2595–2600
6. El Saiedi SA, Mira MF, Sharaf SA, Al Musaddar MM, El Kaffas RMH, AbdelMassih AF, Barsoum IHY. Left ventricular diastolic dysfunction without left ventricular hypertrophy in obese children and adolescents: a tissue doppler imaging and cardiac troponin I study.Cardiol Young. 2018; 28:76–84
7. AbdelMassih AF, Salama KM, Ghobrial C, Haroun B, Rahman MA. Discrepancy in patterns of myocardial involvement in beta-thalassaemia vs. sickle cell anaemia.Acta Cardiol [Internet]. 20191–8
8. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al; ACC; AHA; ASE. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/ASE committee to update the 1997 guidelines for the clinical application of echocardiography).J Am Soc Echocardiogr. 2003; 16:1091–1110
9. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling.Diabetes Care. 2004; 27:1487–1495
10. Kimmel PL, Patel SS. Quality of life in patients with chronic kidney disease: focus on end-stage renal disease treated with hemodialysis.Semin Nephrol. 2006; 26:68–79
11. Demetgul H, Giray D, Delibas A, Hallioglu O. 2D-speckle tracking echocardiography contributes to early identification of impaired left ventricular myocardial function in children with chronic kidney disease.Cardiol Young. 2018; 28:1404–1409
12. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling.J Am Coll Cardiol. 2000; 35:569–582
13. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease.Clin J Am Soc Nephrol. 2007; 2:550–562
14. Stenvinkel P, Zoccali C, Ikizler TA. Obesity in CKD–what should nephrologists know?J Am Soc Nephrol. 2013; 24:1727–1736
15. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.Diabetes Care. 1991; 14:173–194
16. AbdelMassih AF, Attia M, Ismail MM, Samir M. Insulin resistance linked to subtle myocardial dysfunction in normotensive turner syndrome young patients without structural heart diseases.J Pediatr Endocrinol Metab. 2018; 31:1355–1361
17. Jellinger PS. Metabolic consequences of hyperglycemia and insulin resistance.Insulin. 2009; 8:S30–S42
18. Ravera M, Rosa GM, Fontanive P, Bussalino E, Dorighi U, Picciotto D, et al. Impaired left ventricular global longitudinal strain among patients with chronic kidney disease and end-stage renal disease and renal transplant recipients.Cardiorenal Med. 2019; 9:61–68
19. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction.Rev Endocr Metab Disord. 2013; 14:5–12
Keywords:

chronic kidney disease; insulin resistance; left ventricular hypertrophy; subendocardial dysfunction

© 2019Wolters Kluwer Health Lippincott Williams Wilkins